Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novo’s Wegovy Back On Track In Q4 But Broader Supply Issues Remain

Q4 Sales Edge Past Consensus

Executive Summary

Now that US supply of the Danish firm’s blockbuster obesity product is back in full swing, Novo is focusing on diversifying its pipeline to reduce dependence on its GLP-1 franchise.

You may also be interested in...



Lilly Offloads Baqsimi To Amphastar While Investing In Mounjaro Head-To-Head Trial

Although Lilly said the glucagon spray’s relatively low sales were not a factor, the pharma may be prioritizing investment on its newer diabetes and weight-loss drug Mounjaro.

Novo Preempts Earnings Reveal With Preview Of Wegovy-Driven Growth

Novo Nordisk said sales increased 25% in the first quarter, driven by US demand for GLP-1 agonist Wegovy for obesity, and increased its 2023 sales growth guidance from a range of 13%-19% to 24%-30%.

Wegovy CVOT Data Could Pave The Way For Broad Reimbursement, CEO Says

Novo Nordisk CEO Lars Jørgensen discussed the supply and market access position of its rising obesity drug, Wegovy, during the CNBC Health Returns conference.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147837

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel